{"entity":{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","aka":[],"tldr":"Myeloma expert who wrote the diagnostic criteria the field uses and a persistent critic of drug prices.","summary":"S. Vincent Rajkumar is Professor of Medicine in the Division of Hematology at Mayo Clinic and editor-in-chief of Blood Cancer Journal. A haematologist specialising in multiple myeloma and plasma cell disorders, he led the International Myeloma Working Group's updated diagnostic criteria, the criteria the field uses, and the randomised trials establishing lenalidomide-dexamethasone dosing. His papers include the Lancet Oncology report of the International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma and the Lancet Oncology open-label randomised trial of lenalidomide plus high-dose versus low-dose dexamethasone as initial therapy for newly diagnosed myeloma. He is also a persistent critic of drug prices, and his record links to BCMA.","asOf":"2026-09-08","links":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rajkumar%20SV%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=S.%20Vincent%20Rajkumar"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":["bcma"],"drugs":[],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":["mrd-negativity-myeloma","r-iss"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Division of Hematology, Mayo Clinic","institutionId":"mayo-clinic","specialisms":["Multiple myeloma","Plasma cell disorders","Drug pricing"],"profiles":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rajkumar%20SV%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=S.%20Vincent%20Rajkumar"}],"papers":[{"title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","journal":"Lancet Oncology","year":2014,"url":"https://doi.org/10.1016/S1470-2045(14)70442-5","doi":"10.1016/S1470-2045(14)70442-5"},{"title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","journal":"Lancet Oncology","year":2010,"url":"https://doi.org/10.1016/S1470-2045(09)70284-0","doi":"10.1016/S1470-2045(09)70284-0"}]},"route":"/people/vincent-rajkumar/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"institution":[{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/"}],"term":[{"id":"mrd-negativity-myeloma","kind":"term","name":"MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)","route":"/terms/mrd-negativity-myeloma/"},{"id":"r-iss","kind":"term","name":"R-ISS / R2-ISS staging","route":"/terms/r-iss/"}]}}